125 related articles for article (PubMed ID: 37389884)
1. mTOR Inhibition Enhances Delivery and Activity of Antisense Oligonucleotides in Uveal Melanoma Cells.
Dewaele S; Delhaye L; De Paepe B; Bogaert B; Martinez R; Anckaert J; Yigit N; Nuytens J; Van Coster R; Eyckerman S; Raemdonck K; Mestdagh P
Nucleic Acid Ther; 2023 Aug; 33(4):248-264. PubMed ID: 37389884
[TBL] [Abstract][Full Text] [Related]
2. The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival.
Dewaele S; Delhaye L; De Paepe B; de Bony EJ; De Wilde J; Vanderheyden K; Anckaert J; Yigit N; Nuytens J; Vanden Eynde E; Smet J; Verschoore M; Nemati F; Decaudin D; Rodrigues M; Zhao P; Jochemsen A; Leucci E; Vandesompele J; Van Dorpe J; Marine JC; Van Coster R; Eyckerman S; Mestdagh P
Oncogene; 2022 Jan; 41(1):15-25. PubMed ID: 34508176
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S
Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215
[TBL] [Abstract][Full Text] [Related]
4. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.
Amirouchene-Angelozzi N; Nemati F; Gentien D; Nicolas A; Dumont A; Carita G; Camonis J; Desjardins L; Cassoux N; Piperno-Neumann S; Mariani P; Sastre X; Decaudin D; Roman-Roman S
Mol Oncol; 2014 Dec; 8(8):1508-20. PubMed ID: 24994677
[TBL] [Abstract][Full Text] [Related]
5. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
[TBL] [Abstract][Full Text] [Related]
6.
Li P; He J; Yang Z; Ge S; Zhang H; Zhong Q; Fan X
Autophagy; 2020 Jul; 16(7):1186-1199. PubMed ID: 31462126
[TBL] [Abstract][Full Text] [Related]
7. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
[TBL] [Abstract][Full Text] [Related]
8. Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors.
Lobos-González L; Silva V; Araya M; Restovic F; Echenique J; Oliveira-Cruz L; Fitzpatrick C; Briones M; Villegas J; Villota C; Vidaurre S; Borgna V; Socias M; Valenzuela S; Lopez C; Socias T; Varas M; Díaz J; Burzio LO; Burzio VA
Oncotarget; 2016 Sep; 7(36):58331-58350. PubMed ID: 27507060
[TBL] [Abstract][Full Text] [Related]
9. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines.
Smith CS; Golubovskaya VM; Peck E; Xu LH; Monia BP; Yang X; Cance WG
Melanoma Res; 2005 Oct; 15(5):357-62. PubMed ID: 16179862
[TBL] [Abstract][Full Text] [Related]
10. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
11. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.
Amirouchene-Angelozzi N; Frisch-Dit-Leitz E; Carita G; Dahmani A; Raymondie C; Liot G; Gentien D; Némati F; Decaudin D; Roman-Roman S; Schoumacher M
Oncotarget; 2016 Apr; 7(17):23633-46. PubMed ID: 26988753
[TBL] [Abstract][Full Text] [Related]
12. Melanoma addiction to the long non-coding RNA SAMMSON.
Leucci E; Vendramin R; Spinazzi M; Laurette P; Fiers M; Wouters J; Radaelli E; Eyckerman S; Leonelli C; Vanderheyden K; Rogiers A; Hermans E; Baatsen P; Aerts S; Amant F; Van Aelst S; van den Oord J; de Strooper B; Davidson I; Lafontaine DL; Gevaert K; Vandesompele J; Mestdagh P; Marine JC
Nature; 2016 Mar; 531(7595):518-22. PubMed ID: 27008969
[TBL] [Abstract][Full Text] [Related]
13. Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.
Feichtenschlager V; Zheng YJ; Ho W; Chen L; Callanan C; Chen C; Lee A; Ortiz J; Rappersberger K; Ortiz-Urda S
Oncotarget; 2023 May; 14():543-560. PubMed ID: 37235843
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
15. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
Lee J; Gollahon L
Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
[TBL] [Abstract][Full Text] [Related]
16. LINC01278 Induces Autophagy to Inhibit Tumour Progression by Suppressing the mTOR Signalling Pathway.
Liu B; Yao X; Zhang C; Li W; Wang Y; Liao Q; Li Z; Huang Q; Zhang Y; Wu W
Oxid Med Cell Longev; 2023; 2023():8994901. PubMed ID: 36713034
[TBL] [Abstract][Full Text] [Related]
17. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines.
Linnane E; Davey P; Zhang P; Puri S; Edbrooke M; Chiarparin E; Revenko AS; Macleod AR; Norman JC; Ross SJ
Nucleic Acids Res; 2019 May; 47(9):4375-4392. PubMed ID: 30927008
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
19. The Long Non-Coding RNA RHPN1-AS1 Promotes Uveal Melanoma Progression.
Lu L; Yu X; Zhang L; Ding X; Pan H; Wen X; Xu S; Xing Y; Fan J; Ge S; Zhang H; Jia R; Fan X
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28124977
[TBL] [Abstract][Full Text] [Related]
20. Elevated ZNF704 expression is associated with poor prognosis of uveal melanoma and promotes cancer cell growth by regulating AKT/mTOR signaling.
Luo J; Li H; Xiu J; Zeng J; Feng Z; Zhao H; Li Y; Wei W
Biomark Res; 2023 Apr; 11(1):38. PubMed ID: 37038184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
